血友病
參考資料

1 2 3 4  . NHLBI. July 13, 2013  [8 September 2016]. （原始内容存档于2016-10-04）.
1 2 3 4  . CDC. August 26, 2014  [8 September 2016]. （原始内容存档于2016-08-27）.
1 2 3  . NHLBI. July 13, 2013  [8 September 2016]. （原始内容存档于2016-09-17）.
1 2 3 4  . NHLBI. July 13, 2013  [10 September 2016]. （原始内容存档于2016-09-08）.
↑  Franchini, M; Mannucci, PM. . British Journal of Clinical Pharmacology. October 2011, 72 (4): 553–62. PMC 3195733 . PMID 21204915. doi:10.1111/j.1365-2125.2010.03899.x.
↑  Thalji, N; Camire, RM. . Seminars in thrombosis and hemostasis. September 2013, 39 (6): 607–12. PMID 23893775. doi:10.1055/s-0033-1349224.
↑  Franchini, M; Mannucci, PM. . Thrombosis and haemostasis. December 2013, 110 (6): 1114–20. PMID 24008306. doi:10.1160/TH13-05-0363.
↑  Mulliez, SM; Vantilborgh, A; Devreese, KM. . International journal of laboratory hematology. June 2014, 36 (3): 398–407. PMID 24750687. doi:10.1111/ijlh.12210.
1 2  . NHLBI. July 13, 2013  [10 September 2016]. （原始内容存档于2016-09-15）.
1 2 3  . NHLBI. July 13, 2013  [10 September 2016]. （原始内容存档于2016-09-17）.
↑  Peyvandi, F; Garagiola, I; Young, G. . Lancet. 9 July 2016, 388 (10040): 187–97. PMID 26897598. doi:10.1016/s0140-6736(15)01123-x.
1 2 3 4  Wynbrandt, James; Ludman, Mark D. . Infobase Publishing. 1 January 2009: 194  [25 August 2013]. ISBN 978-1-4381-2095-9. （原始内容存档于2021-04-14）.
↑  Douglas Harper. .   [10 October 2007]. （原始内容存档于2008-03-06）.
↑  .   [2014年6月11日]. （原始内容存档于2014年4月9日）.
↑  World Federation of Hemophilia Frequently Asked Questions About Hemophilia （页面存档备份，存于）
↑  .   [2 December 2007]. （原始内容存档于2007-10-12）.
↑  Canadian Hemophilia Society FAQ （页面存档备份，存于）
↑  Den Uijl, I. E. M., Fischer, K., Van Der Bom, J. G., Grobbee, D. E., Rosendaal, F. R., & Plug, I. (2009). Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia, 15(1), 83-90.
↑  Di Minno, M. N. D., Ambrosino, P., Franchini, M., Coppola, A., & Di Minno, G. (2013, October). Arthropathy in patients with moderate hemophilia a: a systematic review of the literature. In Seminars in thrombosis and hemostasis (Vol. 39, No. 07, pp. 723-731). Thieme Medical Publishers.
↑  Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF as- sociation and its clinical implications for hemophilia A. Blood 2016;128:2007-16.
↑  Barbara A. Konkle, M.D., Amy D. Shapiro, M.D.,BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A
↑  Terraube V, O’Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor in- teraction: biological, clinical and thera- peutic importance. Haemophilia 2010;16: 3-13
↑  Seth Chhabra E, Liu T, Kulman J, et al. BIVV001, a new class of factor VIII re- placement for hemophilia A that is inde- pendent of von Willebrand factor in pri- mates and mice. Blood 2020;135:1484-96A
↑  den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemo- philia 2011;17:41-4.
↑  Berntorp, E., Dolan, G., Hay, C., Linari, S., Santagostino, E., Tosetto, A., ... & Albert, T. (2017). European retrospective study of real‐life haemophilia treatment. Haemophilia, 23(1), 105-114.
↑  FELDMAN, B.M., PAI, M., RIVARD, G.E., ISRAELS, S., POON, M.‐C., DEMERS, C., ROBINSON, S., LUKE, K.‐H., WU, J.K.M., GILL, K., LILLICRAP, D., BABYN, P., MCLIMONT, M., BLANCHETTE, V.S. and (2006), Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. Journal of Thrombosis and Haemostasis, 4: 1228-1236. doi:10.1111/j.1538-7836.2006.01953.x
↑  Chia-Yau Chang, Yeu-Chin Chen, Chen-Hua Tsai, Jia-Ruey Tsai, Yen-Lin Liu, Shu-Hsia Hu; The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health. Blood 2019; 134 (Supplement_1): 2406. doi: https://doi.org/10.1182/blood-2019-132137
↑  .   [2020-01-14]. （原始内容存档于2021-04-14）.
↑  . www.gdjyw.com.   [2012-12-24]. （原始内容存档于2021-04-14）.
↑  [http://www.eol.cn/article/20010101/3038833.shtml （页面存档备份，存于）
↑  [永久]
↑  .   [2012-12-24]. （原始内容存档于2021-04-14）.
↑  http://www.china.com.cn/news/txt/2007-11/12/content_9210272.htm （页面存档备份，存于） 基因重组第八因子上市血友病用药短缺有望缓解，中国互联网新闻中心，2007-11-12。
↑  .   [2012-12-25]. （原始内容存档于2006-02-11）.  血友病昨正式纳入广州市基本医疗保险门诊特定项目)
↑  http://right.workercn.cn/c/2012/02/06/120206110415551548878.html （页面存档备份，存于） 石家庄更多慢性病可享受医疗保险，中工网，2012/2/6 《河北工人报》。
↑  http://health.sohu.com/20111231/n330885188.shtml （页面存档备份，存于） 佛山将血友病纳入医保范围限额标准为45000元。sohu新闻，2011-12-31。
↑  http://news.sina.com.cn/c/2012-10-11/021925332266.shtml （页面存档备份，存于） 武汉医保新增16种门诊大病血友病可报销]，sina新闻，2012-10-11，转引自汉网-武汉晚报。内文称自2012年10月1日开始，武汉规定血友病等16种重症（慢性）疾病，在门诊看病时可找医保报销医药费。
↑  http://sciencenow.sciencemag.org/cgi/content/full/2009/1008/2 （页面存档备份，存于） Case Closed: Famous Royals Suffered From Hemophilia